Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

Roam Technologies

Sydney medtech designing JUNO, a pocket-sized tankless oxygen concentrator for chronic respiratory patients, in clinical development with US partners.

Sydney, Australia, OceaniaMedTech & devices, Portable oxygen therapyStartup World Cup Sydney 2026
Stage
Pre-seedNo documented AI
Product
PilotPilots / LOIs
Funding raised
$20Kdisclosed
Founded
201412 years ago
Founders
2Shan-Shan, Natalie
Global score
4.5Grade DRank 63 of 151

Overview

Sydney medtech founded by Shan-Shan Wang that is developing Juno, a portable oxygen device for patients with chronic respiratory diseases, already gaining traction in the US market.

Traction

Pilots / LOIs

JUNO device in clinical development, not approved by the FDA/TGA ("early access" waiting list); partners Texas Medical Center, NSW Health SESLHD, UNSW; Medtech & Pharma 2026 award.

Market

Portable oxygen concentrators

Patients with chronic respiratory diseases need oxygen on the move, but current portable concentrators are heavy and bulky. A much smaller device could improve mobility and adherence. Buyers are payers and durable medical equipment suppliers who handle reimbursement, with clinicians prescribing. Regulatory approval is required before sales.

Addressable market

2025
$2B
2030
$3.3B
+8.39% a year

Portable oxygen concentrators: $2.01bn in 2025, +8.39%/year, $3.25bn in 2030 (Mordor Intelligence).

Customers

COPD and chronic respiratory patients; respiratory clinicians; DME suppliers

Who signs the cheque

Payers (Medicare/insurers), DME suppliers, hospitals

Geographies

  • Australia
  • United States

Drivers

  • Large chronic respiratory population
  • Demand for mobility and quality of life
  • Home-care shift

Headwinds

  • FDA/TGA approval pending
  • Very little capital
  • Reimbursement complexity

Mordor Intelligence estimates portable oxygen concentrators at $2.01bn in 2025 and $3.25bn in 2030 (CAGR 8.4%); publisher range $0.9–3.8bn.

Scalability 5/10. Hardware medical device requiring FDA/TGA clearance and reimbursement country by country; the need (COPD), however, is universal.

Market source: marketresearch.com

Technology

Category

Medical device – respiratory

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

pilot

How it works

JUNO is a pocket-sized tankless oxygen concentrator (no cylinder) for everyday use on the move. It is in clinical development.

Moat

Design IP and clinical partnerships; incumbents have scale.

Differentiation

Pocket-size vs existing portable concentrators.

Integration points

  • Remote patient monitoring
  • DME distribution
  • Power electronics suppliers
  • Respiratory care programmes

Depends on

  • FDA/TGA clearance
  • Battery/power efficiency
  • Manufacturing scale

Use of AI

No use of AI mentioned

Product in detail

Pocket-sized "tankless" oxygen concentrator (no cylinder) for everyday use on the move.

Business

Model
Device sales/rental via DME and payers (future).
Revenue logic
Per-device or rental reimbursement.
Go-to-market
Early-access waiting list; Texas Medical Center, NSW Health SESLHD, UNSW partners.

Next milestones

  1. Regulatory submission
  2. Seed round
  3. Pilot manufacturing

Key risks

  • Regulatory
  • Capital
  • Manufacturing

Opportunities

4 found in the network

Concrete moves for Roam Technologies inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Co-development 1
  • Investors 2
  • Peers 1

Co-development1

An integration or joint product

Explore hybrid power electronics for longer runtime

Battery runtime and peak power for the compressor are a constraint in portable concentrators. Hitt's adaptive supercapacitor-lithium electronics could be tested for peak handling. Speculative, but low-cost to explore.

15%confidence

Evidence from the records

  • “Proprietary power electronics that adaptively integrate supercapacitors with lithium batteries to increase power.”
  • “Pocket-sized "tankless" oxygen concentrator (no cylinder) for everyday use on the move.”
If it works
A technical feasibility assessment.
First step
Share JUNO's power profile with Hitt under NDA.

Investors2

A fund whose thesis fits

Pitch AirTree via ProcurePro

AirTree backs Australian founders from seed to Series B and backed ProcurePro in the network.

30%confidence

Evidence from the records

  • “Backs Australian and New Zealand founders from idea to global scale.”
  • “High risk: FDA/TGA clearance still to be obtained, US$0.02M raised.”
If it works
A leading Australian VC for the seed round.
First step
Ask ProcurePro's founders for an intro to AirTree.

Join StartUp Health via Wink Biotherapeutics

StartUp Health invests at pre-seed/seed in HealthTech globally and backed Wink Biotherapeutics in the network.

25%confidence

Evidence from the records

  • “StartUp Health, Dreamward Ventures”
  • “Well-known clinical partners”
If it works
Investment and access to a health-founder network.
First step
Ask Wink's founders for an intro to StartUp Health.

Peers1

Founders solving the same problem elsewhere

Learn from Byonyks' 2025 FDA class II clearance and US launch set-up

Byonyks obtained FDA 510(k) clearance for a home-therapy device and is setting up US infrastructure, the exact path Roam must follow. A founder exchange can shorten Roam's regulatory and DME launch planning.

30%confidence

Evidence from the records

  • “FDA 510(k) clearance K243371 (decision of 16 May 2025, class II)”
  • “JUNO device in clinical development, not approved by the FDA/TGA ("early access" waiting list); partners Texas Medical Center, NSW Health SESLHD, UNSW; Medtech & Pharma 2026 award.”
If it works
Faster regulatory planning and US launch contacts.
First step
Request a call with Byonyks' regulatory lead.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Sydney early-stage VC backing Australian and New Zealand founders from idea to global scale (Canva, Linktree, ProcurePro).

Australian portable oxygen therapy with Texas Medical Center and NSW Health partners: an ANZ founder going global in medtech. Pre-seed and pre-approval, so regulatory risk is high.

40%confidence

Evidence from the records

  • “Portable oxygen therapy”
  • “partners Texas Medical Center, NSW Health SESLHD, UNSW”
First step
Pitch with a regulatory pathway and first clinical milestones.

Auckland early-stage VC backing Kiwi founders from pre-seed to growth as they build global companies from New Zealand.

Australian portable oxygen medtech — Oceania but not NZ; only fits if Kiwi founders.

25%confidence

Evidence from the records

  • “"Oceania"”
  • “Portable oxygen therapy”
  • “JUNO device in clinical development, not approved by the FDA/TGA ("early access" waiting list)”
Intro path
Founder-to-founder intro via NEOCRETE (network portfolio company of Icehouse Ventures).
First step
Check NZ founder link first.

Australian VC with almost no public profile in our data; its only known deal is ProcurePro's 2026 Series B.

Australian portable oxygen medtech at pre-seed — geography fits, sector and stage are unknowns for Glitch.

20%confidence

Evidence from the records

  • “Australia”
  • “Portable oxygen therapy”
  • “JUNO device in clinical development, not approved by the FDA/TGA ("early access" waiting list)”
Intro path
Founder-to-founder intro via ProcurePro (network portfolio company of Glitch Capital).
First step
Qualify Glitch's sector appetite before pitching.

Liverpool investor with no profile in our data; participated in Ocuwell's 2025 seed.

Australian portable oxygen — medtech, non-UK.

15%confidence

Evidence from the records

  • “Ocuwell”
  • “Portable oxygen therapy”
  • “JUNO device in clinical development, not approved by the FDA/TGA ("early access" waiting list)”
Intro path
Founder-to-founder intro via Ocuwell Limited (network portfolio company of LYVA Labs).
First step
Low priority.

Venture arm of Australian investment manager QIC; led ProcurePro's A$15M Series B in construction-procurement SaaS.

Sydney portable-oxygen medtech; right geography, but early and outside the observed construction thesis.

15%confidence

Evidence from the records

  • “Portable oxygen therapy”
  • “Australia”
First step
Low priority; check QIC's healthcare appetite first.

Investment analysis

4.5D

Grade D

Rank 63 of 151

Disruption6.0/10
Business model3.0/10
Market5.0/10
Risk(lower is better)7.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Promising product but still pre-regulatory: speculative.

Disruption

6/10

JUNO portable oxygen concentrator redesigned through design: significant innovation for respiratory patients.

Business model

3/10

Device in clinical development, not approved, waiting list.

Market

5/10

Score 5/10: TAM $2.01bn → base 4; scalability 5/10 (0); development carried out between Australia and the United States (Texas Medical Center) (+1).

Risk

7/10

Lower is better

High risk: FDA/TGA clearance still to be obtained, US$0.02M raised.

Strengths

  • Well-known clinical partners
  • Award-winning founder (Dyson)

Risks

  • No regulatory clearance
  • Almost no capital

Funding

$20K, disclosed
  1. 2020-01-29

    Angelnot disclosed (PitchBook total $20K)

    not public (PitchBook)

  2. 2025-10

    Accelerator (2 entries)not disclosed

    not public (PitchBook)

  3. 2013

    Prize (James Dyson Award Australia, earlier project)not disclosed

    James Dyson Foundation

Amount used in the study. Total of $20K according to PitchBook (probably incomplete).

Note. ≈ US$20K according to PitchBook (probably incomplete)

verified, nothing to correct (website: JUNO in clinical development, not FDA/TGA-approved, early access); no new funding round found

Team

  • Shan-Shan Wang

    Founder & CEO

    Industrial design graduate (UNSW, First Class); winner of the 2013 Australian James Dyson Award for a lightweight oxygen cylinder for children.

  • Natalie Ho

    Co-founder (according to a podcast)

    Named as co-founder in a podcast listing; background not specified.

Sources

Regional final
Startup World Cup Sydney 2026
Identification confidence
high
Founding year: 2014 (medium confidence)
Founded in 2014 according to PitchBook (launched by Shan-Shan Wang the year after her studies); no ASIC check. pitchbook.com
  1. 1startupdaily.net/topic/events/from-sydney-to-silicon-valley-medtech-founder-
  2. 2roamtech.ai/

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet